Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R4OM
|
||||
| Former ID |
DAP000034
|
||||
| Drug Name |
Trifluoperazine
|
||||
| Synonyms |
Calmazine; Eskazine; Fluoperazine; Flurazine; Modalina; Stelazine; Stellazine; TFP; Trifluoperazin; Trifluoperazina; Trifluoperazinum; Trifluoromethylperazine; Trifluoroperazine; Trifluperazine; Triflurin; Trifluroperizine; Triftazin; Triftazine; Triperazine; Triphtazin; Triphtazine; Triphthasine; PMS Trifluoperazine; Stelazine Concentrate; Trifluoperazina [Italian]; Trifluoperazine HCl; Trifluoperazine dihydrochloride; Trifluoroperazine dihydrochloride; Tripfluoperazine Hydrochloride; NCI17474; RP 7623; SKF 5019; Apo-Trifluoperazine; Eskazine (TN); Eskazinyl (TN); Jatroneural (TN); Modalina (TN); Novo-Trifluzine; Stelazine (TN); Terfluzine (TN); Trifluoperaz (TN); Trifluoperazina [INN-Spanish]; Trifluoperazine (INN); Trifluoperazine [INN:BAN]; Trifluoperazinum [INN-Latin]; Apo-trifluoperazine (TN); Stelazine (*Dihydrochloride*); Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine; 10-(3-(4-Methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-10H-phenothiazine; 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-phenothiazine; 10-(gamma-(N'-Methylpiperazino)propyl)-2-trifluoromethylphenothiazine; 10-[3-(4-METHYL-PIPERAZIN-1-YL)-PROPYL]-2-TRIFLUOROMETHYL-10H-PHENOTHIAZINE; 10-[3-(4-Methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)-10H-phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine; 10-[3-(4-methylpiperazin-1-yl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride; 2-Trifluoromethyl-10-(3'-(1-methyl-4-piperazinyl)propyl)phenothiazine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Schizophrenia; Generalized non-psychotic anxiety [ICD10:F20] | Approved | [1] | ||
| Therapeutic Class |
Antipsychotic Agents
|
||||
| Company |
GlaxoSmithKline plc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H24F3N3S
|
||||
| InChI |
InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3
|
||||
| InChIKey |
ZEWQUBUPAILYHI-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 117-89-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9377, 602753, 841996, 4252673, 5664287, 7890752, 7980830, 10319712, 10505141, 11110644, 11110645, 11120338, 11120826, 11121314, 11121780, 11122260, 11336018, 11361257, 11362944, 11363562, 11364843, 11365506, 11366124, 11367405, 11368068, 11368686, 11369967, 11371059, 11371060, 11372247, 11373007, 11373669, 11373974, 11375567, 11376230, 11376848, 11378135, 11405822, 11408478, 11458546, 11460495, 11462229, 11466341, 11467461, 11484491, 11486261, 11488644, 11491189, 11492183, 11494482
|
||||
| ChEBI ID |
ChEBI:45951
|
||||
| SuperDrug ATC ID |
N05AB06
|
||||
| SuperDrug CAS ID |
cas=000117895
|
||||
| Target and Pathway | |||||
| Target(s) | Calmodulin | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Calcium signaling pathway | |||||
| cGMP-PKG signaling pathway | |||||
| cAMP signaling pathway | |||||
| Phosphatidylinositol signaling system | |||||
| Oocyte meiosis | |||||
| Adrenergic signaling in cardiomyocytes | |||||
| Vascular smooth muscle contraction | |||||
| Circadian entrainment | |||||
| Long-term potentiation | |||||
| Neurotrophin signaling pathway | |||||
| Dopaminergic synapse | |||||
| Olfactory transduction | |||||
| Phototransduction | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Insulin signaling pathway | |||||
| GnRH signaling pathway | |||||
| Estrogen signaling pathway | |||||
| Melanogenesis | |||||
| Oxytocin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Salivary secretion | |||||
| Gastric acid secretion | |||||
| Alzheimer's disease | |||||
| Amphetamine addiction | |||||
| Alcoholism | |||||
| Pertussis | |||||
| Tuberculosis | |||||
| Glioma | |||||
| NetPath Pathway | RANKL Signaling Pathway | ||||
| TSH Signaling Pathway | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Pathway Interaction Database | BCR signaling pathway | ||||
| p38 MAPK signaling pathway | |||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Role of Calcineurin-dependent NFAT signaling in lymphocytes | |||||
| IL2 signaling events mediated by PI3K | |||||
| IFN-gamma pathway | |||||
| Lissencephaly gene (LIS1) in neuronal migration and development | |||||
| ErbB1 downstream signaling | |||||
| VEGFR1 specific signals | |||||
| Regulation of cytoplasmic and nuclear SMAD2/3 signaling | |||||
| Calcium signaling in the CD4+ TCR pathway | |||||
| Signaling events mediated by VEGFR1 and VEGFR2 | |||||
| Insulin-mediated glucose transport | |||||
| N-cadherin signaling events | |||||
| Cellular roles of Anthrax toxin | |||||
| Regulation of Ras family activation | |||||
| Downstream signaling in naï | |||||
| PathWhiz Pathway | Muscle/Heart Contraction | ||||
| Reactome | Calmodulin induced events | ||||
| Platelet degranulation | |||||
| Translocation of GLUT4 to the plasma membrane | |||||
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | |||||
| DARPP-32 events | |||||
| eNOS activation | |||||
| Inactivation, recovery and regulation of the phototransduction cascade | |||||
| FCERI mediated Ca+2 mobilization | |||||
| Ca2+ pathway | |||||
| CREB phosphorylation through the activation of CaMKII | |||||
| Ras activation uopn Ca2+ infux through NMDA receptor | |||||
| Smooth Muscle Contraction | |||||
| VEGFR2 mediated vascular permeability | |||||
| VEGFR2 mediated cell proliferation | |||||
| RHO GTPases activate IQGAPs | |||||
| RAF/MAP kinase cascade | |||||
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
| WikiPathways | Translocation of GLUT4 to the Plasma Membrane | ||||
| Visual phototransduction | |||||
| Fc epsilon receptor (FCERI) signaling | |||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Signaling by the B Cell Receptor (BCR) | |||||
| Inositol phosphate metabolism | |||||
| DAG and IP3 signaling | |||||
| Opioid Signalling | |||||
| Muscle contraction | |||||
| Metabolism of nitric oxide | |||||
| Metabolism of carbohydrates | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med. 2003 Aug;69(8):692-5. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.